Four profitable investment options in the Eastern regions.
In a strategic move to capitalise on China's economic transition, the renowned asset management firm Carmignac has identified a series of high-quality domestic companies that stand to benefit from the country's focus on digitalization, middle-class consumption, green revolution, and healthcare & medical innovation. This investment approach is primarily spearheaded by Carmignac's fund, the "Carmignac Portfolio China New Economy."
The fund, which invests in domestic companies aligned with the new economy themes, favours companies leading in advanced technologies like robotics, autonomous driving, and biotech innovation. China's innovation push, particularly in AI and healthcare biotech IP, is highlighted as a significant growth driver.
In the realm of middle-class consumption, the fund targets quality domestic companies with high income visibility serving the growing Chinese middle class, focusing on consumer discretionary sectors benefiting from rising incomes and urbanization.
For those championing sustainability and green initiatives, Carmignac's sustainable investing approach incorporates environmental, social, and governance (ESG) criteria, implying investments in firms contributing to green technology and energy transition.
In the healthcare and medical innovation sector, Carmignac emphasizes biotech and healthcare innovation in China, viewing it as globally competitive with “global firsts” in some niches. This area is seen as parallel to the information technology sector in potential and innovation.
While specific company names are not disclosed in the provided results, the investment themes focus on companies capitalising on China’s strategic economic transformation with a strong sustainability and innovation orientation.
In addition to the "Carmignac Portfolio China New Economy" fund, Carmignac's "Asia Discovery" fund also offers broader Asia exposure, which includes some Chinese companies, holding significant stakes in information technology and consumer discretionary sectors, indirectly supporting digitalization and growing consumption.
China's position as the world's second-largest economy, with a market capitalization of $19 trillion, and a population of 1.4 billion, makes it one of the world's largest consumer markets. The Chinese government aims to expand its domestic market to boost consumption through increased purchasing power and improved living standards.
The biotechnology sector in China is experiencing increased investment in research and development, with companies like Chongqing Zhifei Biological and WuXi Biologics attracting interest. The government also plans to increase investments in R&D and high-tech manufacturing sectors, including semiconductors, data centers, 5G, photovoltaics, and alternative energies.
Moreover, China sees the shift to clean energy and electric mobility as an opportunity to lead in these sectors, with all new vehicles sold in China by 2035 to be "environmentally friendly." The government aims to reach 3 billion kilowatts of wind power capacity by 2060 and improve resource efficiency.
The Chinese BATX companies (Baidu, Alibaba, Tencent, and Xiaomi) are challenging the dominance of US tech giants, while the Carmignac Emergents fund is interested in aviation provider Ehang in the electric mobility sector. ENN Energy and Flat Glass Group are companies of interest in the clean energy sector.
In conclusion, Carmignac's strategic approach to investing in the Chinese new economy reflects a focus on high-quality domestic companies that capitalise on China's economic transition, particularly in sectors aligned with the new economy themes such as innovation (technology), consumer growth, green initiatives, and healthcare breakthroughs.
The "Carmignac Portfolio China New Economy" fund invests in domestic companies leading in advanced technologies like robotics, autonomous driving, and biotech innovation, recognizing China's innovation push in AI and healthcare biotech IP as a significant growth driver.
Additionally, China's biotechnology sector, with companies like Chongqing Zhifei Biological and WuXi Biologics attracting interest, is experiencing increased investment in research and development, aligning with Carmignac's sustainable investing approach that incorporates investments in firms contributing to green technology and energy transition.
